Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P18850
UPID:
ATF6A_HUMAN
Alternative names:
Activating transcription factor 6 alpha
Alternative UPACC:
P18850; O15139; Q5VW62; Q6IPB5; Q9UEC9
Background:
Cyclic AMP-dependent transcription factor ATF-6 alpha, also known as Activating transcription factor 6 alpha, plays a crucial role in cellular stress response. Embedded in the endoplasmic reticulum membrane, it activates genes involved in the unfolded protein response (UPR) upon stress, crucial for maintaining cellular function.
Therapeutic significance:
ATF-6 alpha's involvement in Achromatopsia 7, characterized by colorblindness and low visual acuity, highlights its potential in ocular disease therapy. Understanding its role could open doors to innovative treatments for retinal disorders.